{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-106910","form_type":"8-K","ticker":"KRRO","cik":"0001703647","company_name":"Korro Bio, Inc.","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.717418+00:00","generated_at":"2026-05-17T14:41:05.809457+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Korro Bio Q2 2025 net loss $25.8M; cash $119.6M; KRRO-110 interim data on track H2 2025","bullets":["Cash, cash equivalents and marketable securities of $119.6M as of June 30, 2025, expected to fund operations into 2027.","Net loss $25.8M for Q2 2025 vs $21.8M in Q2 2024; R&D expenses $21.0M (up from $17.1M).","Collaboration revenue of $1.5M from Novo Nordisk partnership; zero collaboration revenue in prior year quarter.","Phase 1/2a REWRITE trial of KRRO-110 for AATD: over 80% of planned healthy volunteers dosed; interim SAD readout expected H2 2025.","KRRO-110 received EMA Orphan Drug Designation for AATD; rare metabolic disorder development candidate to be announced by end of 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-106910","json":"https://secwatch.observer/filing/0000950170-25-106910.json","markdown":"https://secwatch.observer/filing/0000950170-25-106910.md","text":"https://secwatch.observer/filing/0000950170-25-106910.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703647/000095017025106910/0000950170-25-106910-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703647/000095017025106910/krro-20250812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:41:05.809457+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}